Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Vertongen

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Biochemical Society Transactions|August 28, 2002
A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effectorI Langer, P Vertongen, J Perret, et al.
Cell Calcium|October 6, 2001
Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16I Langer, J Perret, P Vertongen, et al.
Neuropeptides|October 1, 1996
VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptorP Vertongen, I Camby, F Darro, et al.
Neuropharmacology|February 1, 2003
Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonistsI Langer, P Vertongen, J Perret, et al.
Biochemical Society Transactions|August 28, 2002
Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutationsM Waelbroeck, J Perret, P Vertongen, et al.
Medical and Pediatric Oncology|June 8, 2000
Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomasI Langer, P Vertongen, J Perret, et al.
American Heart Journal|February 1, 1995
A new transvenous internal cardioverter-defibrillator: implantation technique, complications, and short-term follow-upL Jordaens, P Vertongen, F Provenier, et al.
British Journal of Pharmacology|August 11, 2001
Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helixP Vertongen, R M Solano, J Perret, et al.
Peptides|August 22, 2001
Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structureP Vertongen, R M Solano, M G Juarranz, et al.
British Heart Journal|January 1, 1993
Experience of cardioverter-defibrillators inserted without thoracotomy: evaluation of transvenously inserted intracardiac leads alone or with a subcutaneous axillary patchL Jordaens, J W Trouerbach, P Vertongen, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Biochemical Society Transactions|August 28, 2002
A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effectorI Langer, P Vertongen, J Perret, et al.
Cell Calcium|October 6, 2001
Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16I Langer, J Perret, P Vertongen, et al.
Neuropeptides|October 1, 1996
VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptorP Vertongen, I Camby, F Darro, et al.
Neuropharmacology|February 1, 2003
Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonistsI Langer, P Vertongen, J Perret, et al.
Biochemical Society Transactions|August 28, 2002
Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutationsM Waelbroeck, J Perret, P Vertongen, et al.
Medical and Pediatric Oncology|June 8, 2000
Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomasI Langer, P Vertongen, J Perret, et al.
American Heart Journal|February 1, 1995
A new transvenous internal cardioverter-defibrillator: implantation technique, complications, and short-term follow-upL Jordaens, P Vertongen, F Provenier, et al.
British Journal of Pharmacology|August 11, 2001
Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helixP Vertongen, R M Solano, J Perret, et al.
Peptides|August 22, 2001
Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structureP Vertongen, R M Solano, M G Juarranz, et al.
British Heart Journal|January 1, 1993
Experience of cardioverter-defibrillators inserted without thoracotomy: evaluation of transvenously inserted intracardiac leads alone or with a subcutaneous axillary patchL Jordaens, J W Trouerbach, P Vertongen, et al.
Pageof 4